NRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines
£2.68 million Biomedical Catalyst (BMC) early-stage award funded in part by Innovate UK to support development of disease-modifying...
Parkinson’s UK and Domainex collaborate to develop therapies targeting neuroinflammation
3 February 2022 Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, and Domainex Ltd., today announce a...
Parkinson’s UK invests £185K in new company to develop therapies targeting lysosomal dysfunction
25 January 2022 Through its innovative Parkinson’s Virtual Biotech, Parkinson’s UK is investing £185,000 in EndLyz Therapeutics, Inc....
Parkinson’s UK invests up to £3 million in a promising project which could slow progression
7 December 2021 Parkinson’s UK, Europe’s largest charitable funder of research into the condition, is leading a project to develop...
First Patient Dosed in Phase 2a Trial of NLX-112 for the Treatment of L-DOPA Induced Dyskinesia
November 30, 2021 Neurolixis, a clinical-stage biopharmaceutical company focused on advancing novel therapies to treat central nervous...
